Evogene Launches Its New Branding to Reflect the Company’s Expanded Vision and New Business Model

REHOVOT, Israel, Might 20, 2020 /PRNewswire/ — Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN.TA), a number one computational biology firm concentrating on to revolutionize life-science product growth throughout a number of market segments, broadcasts right now its rebranding. The brand new company identification displays the corporate’s expanded imaginative and prescient and new enterprise mannequin.

“Evogene has undergone a major transformation in its providing over the previous years, and we’re actively working to painting our expanded imaginative and prescient and technique to the enterprise and funding neighborhood. I imagine that this new branding represents our new providing and can serve us extraordinarily properly in speaking this to the broader market,” said Ofer Haviv, President & CEO of Evogene.

Established as a spin-off from Compugen Ltd. in 2002, Evogene was initially targeted on making use of its capabilities in computational biology in agriculture, and extra particularly on bettering seed traits based mostly on genomic modification. Adjustments within the agriculture market and in shopper tastes and demand necessitated that Evogene broaden its imaginative and prescient and concentrate on a number of new goal markets and segments. The numerous capital raised in its 2013 IPO allowed the Firm to execute this technique, enhancing its expertise and increasing to new market segments.

Within the years that adopted, the Firm’s administration took a sequence of steps that paved the trail for its evolution. Two key choices underlay this growth; the primary was increasing Evogene’s technological capabilities in computational biology to incorporate growth of merchandise based mostly on microbes and small molecules, along with genomics, and the second was to increase Evogene’s focus past agriculture, to human well being. These choices led to the creation of Evogene’s amassed computational biology capabilities – the CPB (Computational Predictive Biology) platform, which goals to considerably enhance the likelihood of success, whereas lowering time and value, of life-science product growth. In parallel, the Firm established numerous inside divisions, every main the event of particular market-driven merchandise whereas utilizing the CPB platform as their aggressive benefit.

In 2018, Evogene introduced the revision of its company construction to accommodate its new broadened actions. The Firm started the execution of this plan by establishing new devoted subsidiaries, based mostly on the actions of its current divisions, specializing in downstream product growth. 4 new subsidiaries had been established within the areas of human well being and agriculture, together with (so as of firm): Biomica, AgPlenus, Lavie Bio and Canonic, becoming a member of Evogene’s earlier subsidiary, Casterra. In parallel, Evogene continued to concentrate on enhancements to its CPB platform, serving as a technological hub for use by the entire group by means of licensing agreements.

Mr. Haviv continued, “At the moment, Evogene supplies tailored computational-biology options for the invention and growth of merchandise based mostly on microbes, small molecules and genetic components for life-science based mostly industries, together with: human well being, agriculture and industrial purposes.

“I imagine that we’re better-positioned than ever earlier than to seize the worth of our distinctive expertise in two distinct methods – by means of our current collaborations and thru our unbiased subsidiaries. Now we have a number of upcoming key milestones throughout our subsidiaries, which we imagine will generate substantial worth. Particulars on these milestones can be found in our newly branded presentation, filed right now.

“We are actually able to proceed to harness the ability of our CPB platform by means of further collaborations with strategic companions and to learn as a shareholder from our subsidiaries as their worth is unlocked and turns into obvious,” Mr. Haviv concluded.

About Evogene Ltd.:

Evogene (NASDAQ: EVGN) (TASE: EVGN.TA) is a number one computational biology firm concentrating on to revolutionize product growth for life-science based mostly industries, together with human well being, agriculture, and industrial purposes. Incorporating a deep understanding of biology and leveraging Large Information and Synthetic Intelligence, Evogene established its distinctive expertise, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally uncover and develop life-science merchandise based mostly on microbes, small molecules and genetic components because the core parts for such merchandise. Evogene holds various subsidiaries using the CPB platform, for the event of human microbiome-based therapeutics, medical hashish, ag-biologicals, ag-chemicals, seed traits and ag-solutions for castor oil manufacturing.

For extra info, please go to www.evogene.com

Ahead Wanting Statements:

This press launch comprises “forward-looking statements” regarding future occasions. These statements could also be recognized by phrases similar to “might”, “might”, “expects”, “intends”, “anticipates”, “plans”, “believes”, “scheduled”, “estimates” or phrases of comparable that means. For instance, Evogene is utilizing forward-looking statements on this press launch when it discusses capturing the worth of its applied sciences, entering into collaboration agreements and its upcoming milestones. Such statements are based mostly on present expectations, estimates, projections and assumptions, describe opinions about future occasions, contain sure dangers and uncertainties that are tough to foretell and will not be ensures of future efficiency. Due to this fact, precise future outcomes, efficiency or achievements of Evogene and its subsidiaries might differ materially from what’s expressed or implied by such forward-looking statements as a consequence of a wide range of components, a lot of that are past the management of Evogene and its subsidiaries, together with, with out limitation, the worldwide unfold of COVID-19, or the Coronavirus, the varied restrictions deriving therefrom and people danger components contained in Evogene’s reviews filed with the relevant securities authorities. As well as, Evogene and its subsidiaries rely, and anticipate to proceed to rely, on third events to conduct sure actions, similar to their field-trials and pre-clinical research, and if these third events don’t efficiently perform their contractual duties, adjust to regulatory necessities or meet anticipated deadlines (together with because of the impact of the Coronavirus), Evogene and its subsidiaries might expertise vital delays within the conduct of their actions. Evogene and its subsidiaries disclaim any obligation or dedication to replace these forward-looking statements to mirror future occasions or developments or modifications in expectations, estimates, projections and assumptions.

View unique content material:http://www.prnewswire.com/news-releases/evogene-launches-its-new-branding-to-reflect-the-companys-expanded-vision-and-new-business-model-301062463.html

SOURCE Evogene

Firm Codes: TelAviv:EVGN, NASDAQ-NMS:EVGN